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8 Oral Presentationscumulative incidence of transplant related-mortality and relapse
was 9.96 4%, 24.86 5%, respectively. Inmultivariate analyses, ad-
vanced disease status was an adverse factor for DFS (p5 0.001) and
relapse (p5 0.007). These results suggest that adult acute leukemia
patients without suitable related or unrelated bone marrow donors
should be considered as candidates for CBT.
15
THE IMPACT OF RESOLVED HEPATITIS B INFECTION ON ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMATOLOGI-
CAL MALIGNANCIES
Ramos, C.A., Saliba, R.M., Giralt, S., Khorshid, O., de Padua, L.,
Andersson, B.S., Nieto, Y.L., Popat, U.R., Qazilbash, M.H.,
Qureshi, S., Zhang, W., Champlin, R.E., de Lima, M. The University
of Texas MD Anderson Cancer Center, Houston, TX.
Serological evidence of resolved hepatitis B (HB) infection has
been associated with reactivation of hepatitis after allogeneic SCT
(alloSCT), but the true impact of this finding is unknown. We hy-
pothesized that reactivation of HB could lead to worse outcomes in
patients following alloSCT.
We conducted a retrospective matched-control analysis of the
outcomes of 77 patients with positive HB core antibody (HBcAb)
and negative HB surface antigen (HBsAg) at the time of alloSCT.
All patients had hematological malignancies (including AML,
CML, lymphoma, ALL, CLL and myeloma) and were transplanted
between 1998 and 2007. Control patients (with negative serology
for HB and other viral hepatitides) were matched by age, diagnosis,
disease risk (poor vs. good), intensity of conditioning regimen (re-
duced vs. myeloablative) and donor type. Poor risk was defined as
not being in remission or not having chemosensitive tumor before
transplant, depending on the specific disease. When possible, if
multiple matches were available, a control patient with the same ex-
act disease stage, conditioning regimen and graft source (blood or
bone marrow) was selected. Three patients were dropped from
the comparison because no appropriate matched control was avail-
able.
The control and study groups had similar baseline patient charac-
teristics regarding age (median 50 and 49, respectively), poor risk
(51% in both groups), sibling donor (73%), reduced intensity con-
ditioning (42%) and diagnosis. Follow-up serological studies done
after transplant documented reactivation of hepatitis B (defined as
the emergence of positive HBsAg) in 8 (10%) of the initially HBcAb
positive and HBsAg negative patients. Two of these patients re-
verted back to HBsAg negativity after a period of moderate eleva-
tion of liver enzymes and are long term survivors. The other 6
patients had persistent mild elevation of ALT and AST: 2 became
long term survivors, 2 died of chronic GVHD (with liver involve-
ment) and 2 died from progression of disease. Loss of antibody re-
sponse to HBc antigen with persistent negativity of HBsAg was
documented in 23 patients (30%). There were no significant differ-
ences in overall survival, relapse and non-relapse mortality and in-
cidence of acute GVHD between HBcAb positive and control
groups. In conclusion, positive HBcAb status at the time of trans-
plant does not seem to adversely affect outcomes, despite being as-
sociated with reactivation ofHB infection in at least 10% of patients
after alloSCT.
Overall survival and non-relapse mortality are comparable in HepBcAb
positive patients and matched controls after SCT
Outcome HepBcAb, % Control, % HR (95% CI) POS:
1 yr 66 64 0.99 (0.6–1.7) 0.9
2 yr 51 55 1.1 (0.7–1.8) 0.7NRM:
3 mo 11 5 2.1 (0.6–6.9) 0.2
1 yr 25 17 1.5 (0.7–3.1) 0.3
2 yr 31 21 1.5 (0.7–3.1) 0.3OS: overall survival; NRM: non-relapse mortality; HR: hazard
ratio; CI: confidence interval.16
LONG-TERM RESULTS OF A GITMO RETROSPECTIVE STUDY ON HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR PAROXYSMAL
NOCTURNAL HEMOGLOBINURIA (PNH)
Santarone, S.1, Di Bartolomeo, E.1, Bacigalupo, A.2, Tagliaferri, E.3,
Iori, A.4, Risitano, A.5, Tamiazzo, S.6, Papineschi, F.7, Rambaldi, A.8,
Spagnoli, A.9, Angelucci, E.10, Di Bartolomeo, P.1. 1BMT Center, Pes-
cara, Italy; 2BMT Center, Genova, Italy; 3BMT Center, Milano, Italy;
4BMTCenter, University La Sapienza, Roma, Italy; 5BMTCenter, Na-
poli, Italy; 6BMT Center, Alessandria, Italy; 7BMT Center, Pisa, Italy;
8BMT Center, Bergamo, Italy; 9BMT Center, S.Eugenio Hospital,
Roma, Italy; 10BMT Center, Cagliari, Italy.
Allogeneic HSCTmay cure PNH. In this study we report the re-
sults of allogeneic HSCT in 26 patients (16 males and 10 females)
affected by PNH who were transplanted between July 1988 and
May 2007. The median age at time of HSCT was 32 years (20–
60). The median time from diagnosis to HSCT was 33 months
(3–208). All patients had received various treatments before
HSCT including steroids, immunosuppressive drugs and growth
factors. Twenty-one patients were transfusion-dependent. The me-
dian number of packed red blood cells and platelet concentrates re-
ceived before HSCT was 30 (4–500) and 22 (6–86) respectively. At
time of HSCT, the median peripheral hematological counts were:
polymorphonucleates (PMN) 2200 (20–10204)  109/L, hemoglo-
bin 8.7 g/dl (4.6–11), platelets (PLT) 78 (6–355)  109/L. Two pa-
tients were severely pancytopenic at time of HSCT. Twenty-four
patients were transplanted from HLA identical siblings and 2
from matched unrelated donors. The donor’s median age was 33
years (20–59). The conditioning regimen was myeloablative for
16 patients (Busulfan and Cyclophosphamide), whereas 10 patients
received a reduced intensity conditioning including Fludarabine,
Cyclophosphamide, Melphalan and Total Body Irradiation. As
graft-versus-host disease (GvHD) prophylaxis, 11 patients received
Cyclosporine (CSA) alone and 13 were given CSA and short course
Methotrexate. Two patients received T-cell depleted marrow cells.
Twenty patients were given bone marrow cells (median nucleated
cells 4.1 (2.5–7.5)  108/kg) and 6 received peripheral blood stem
cells (median CD341 cells 4.6 (2.8–7.1)  106/Kg). Twenty-five
patients achieved primary sustained engraftment with a median
time of 17 (10–38) days to reach .0.5  109/L PMN and 27 (11–
322) days to reach .50  109/L PLT. The probability of develop-
ing grade II-IV acute GvHDand extensive chronicGvHDwas 42%
and 16% respectively. The transplant related mortality at 6 months
was 34%. Causes of death were infection in 4 patients, acute GvHD
in 1, chronicGvHD in 2, multi-organ failure in 1 and EBV lympho-
proliferative disease in 1. As of October 2007, 16 patients are alive
with complete hematological recovery and no evidence of PNH at
a median follow-up of 107 months (6–210). The 10-year Kaplan-
Meier probability of disease-free survival is 62%. No patient devel-
oped thromboembolic disease following HSCT. This study con-
firms that HSCT is a curative treatment for the majority of
patients with PNH.17
PRE-TRANSPLANT INFUSION OF NATURALLY OCCURRING DONOR
CD41 CD251 T CELLS SUPPORTS DONOR CHIMERISM IN MHC-
MATCHED ALLOGENEIC HCT
Shatry, A.M., Levy, R.B. University of MiamiMiller School of Medicine,
Miami, FL.
Resistance to MHC matched allogeneic hematopoietic stem cell
transplant (HCT) is mediated by host T cells and remains a major
complication to successful donor HCT engraftment under reduced
intensity conditioning. We examined the ability of unmanipulated
donor CD41 CD251 regulatory T cells (Tregs) to support donor
HCT engraftment to test the hypothesis that Treg suppression of
host effector CD81 T anti-donor responses would enhance donor
HCT engraftment. Mice disparate for multiple minor HA were uti-
lized for these studies: C57BL/6 (H-2b, Ly9.1-) mice conditioned
(5.5 Gy TBI) 24 hrs earlier, were transplanted with Tregs and
TCD-BM from 129P3/J (H-2b, Ly9.11) mice. By four weeks
post-HCT, the mean frequency of circulating donor-derived (total
Ly9.11) cells was significantly higher in recipients of 4  106
Oral Presentations 9TCD-BM1Tregs (4.5 105) compared to recipients of allogeneic
HCT only (p\ 0.05). We next examined the effects of pre-HCT
infusion of Tregs: Tregs (4 or 1.5  105) were transplanted 24 hr.
post-conditioning either 3 days pre-HCT or co-transplanted with
(day 0) donor TCD-BM. Although no difference was observed us-
ing higher Treg doses, pre-infusion - but not co-transplant of low
Treg doses was able to induce chimerism in these recipients. One
month post-HCT of TCD-BM alone, the frequency of circulating
host anti-donor tetramer1 (the immunodominant epitope H60)
CD81 cells in these recipients rejecting themarrow graft was clearly
greater compared to recipients of TCD-BM1Tregs both of which
engrafted (p\ 0.0008). However, the host anti-donor CD8 levels
were equivalent in recipients of TCD-BM alone and TCD-BM 1
Day 0 low doseTreg administration which failed to engraft. Nota-
bly, transplants using unmanipulated host Tregs failed to support
engraftment. These findings indicate that donor Tregs support chi-
merism via suppression of host anti-donor antigen-specific T cells.
Finally, the persistence of donor cells in circulation as well as in lym-
phoid tissues 3 months post-HCT indicated that long-term, stable
chimerism was established by this pre-HCT Treg regimen.
Together, our results demonstrate that donor Tregs promote
MHC-matched allogeneic marrow engraftment by suppressing
host anti-donor responses. Thus, the strategy of pre-HCTTreg in-
fusion is consistent with the notion that antigen-driven expansion of
donor anti-host reactive Treg cells can enhance hematopoietic en-
graftment. We are currently investigating host Treg expansion in
MHC-matched HCT recipients.AUTOLOGOUS TRANSPLANTS18
UTILITY OF CO-MORBIDITY ASSESSMENT IN PREDICTING TRANS-
PLANT-RELATED TOXICITY FOLLOWING AUTOLOGOUS HEMATOPOI-
ETIC TRANSPLANTATION FOR MULTIPLE MYELOMA
Labonte, L.1, Iqbal, T.2, Zaidi, M.A.1, McDiarmid, S.A.2,
Huebsch, L.B.2, Tay, J.2, Allan, D.S.1,2. 1Ottawa Health Research Pro-
gram, Ottawa, ON, Canada; 2University of Ottawa/The Ottawa Hospi-
tal, Ottawa, ON, Canada.
Background: Several randomized studies have demonstrated the
benefits and favorable toxicity following autologous hematopoietic
stem cell transplantation (AHSCT) for patients with multiple mye-
loma (MM)who are less than 55 yrs. Treatment related toxicity may
increase for older patients with co-morbidities and the benefits of
AHSCT become debatable. Decision tools for identifyingmyeloma
patients most suitable for AHSCT are needed to avoid the risk of
excess toxicity.Methods:Data regarding co-morbidities and toxic-
ity following transplant were extracted from the hospital records
and BMT database from 126 patients with MM undergoing
AHSCT between 1994 and 2006. All patients consented to the
use of medical information for research purposes. Co-morbidity
was assessed using the Charlson Co-morbidity Index (CCI), the
Haematopoietic Cell Transplantation Co-morbidity Index
(HCT-CI) and a modified Pretransplantation Assessment of Mor-
tality (mPAM). Transplant-related toxicity was assessed using
length of hospital stay (LOS) following the transplant, the total
number of organs having any toxicity according to the Seattle crite-
ria, cumulative toxicity using the scores in 8 organ systems, and non-
relapse mortality at 100 days. Results: Any co-morbidity using the
CCI (score. 0) was associated with prolonged LOS (OR 4.05, 1.76
– 9.29 for LOS greater than 18 days), more organ systems with any
toxicity (OR 2.27, 0.99 – 5.22 for at least one organ), and greater cu-
mulative organ toxicity (OR 2.2, 1.06 – 4.49 for total score $2).
Likewise, any co-morbidity using the HCT-CI (score . 0) was
also associated with longer LOS (OR 5.34, 2.24 – 12.75), increased
organ systemswith any toxicity (OR 2.5, 1.08 – 5.80) and cumulative
overall toxicity (OR 2.22, 1.08 – 4.55). A score of $24 using the
mPAM was associated with increased LOS (OR 3.03, 1.35 – 6.77)
but not with an increased number of organs with any toxicity or
with cumulative toxicity. None of the co-morbidity assessment
scales was associated with non-relapse mortality due to low inci-
dence of transplant-related death in this group (2 deaths or 1.6%).
Conclusion: Any co-morbidity identified using the CCI andHCT-CI was associated with greater toxicity following autologous
transplant for multiple myeloma. None of the scales was associated
with increasedmortality in this group. In discussingAHSCT for pa-
tients with myeloma, assessment of co-morbidities using the CCI or
HCT-CI may assist in determining the risk of toxicity.GRAFT PROCESSING19
PHARMACOLOGIC INHIBITION OF ALDEHYDE DEHYDROGENASE
(ALDH) CAUSES THE EXPANSION OF HEMATOPOIETIC STEM CELLS
(HSCs) WITH ENHANCED ENGRAFTMENT CAPACITY
Muramoto, G.G., Himburg, H., Meadows, S., Salter, A., Chao, N.J.,
Chute, J.P. Duke University, Durham, NC.
Delayed engraftment and graft failure are persistent obstacles
which limit the application of umbilical cord blood (CB) transplan-
tation in adults. We recently demonstrated that inhibition of
ALDH with diethylaminobenzaldehyde (DEAB) induced the ex-
pansion of human HSCs capable of repopulating NOD/SCID
mice (PNAS 2006 103:11707). In this study, we utilized syngeneic
CD45.1/CD45.2 mice to determine whether inhibition of ALDH
could accelerate the engraftment of transplantedHSCs in vivo. Cul-
ture of murine c-kit1sca-11lin-CD34- (34-KSL) cells with 100
mM DEAB coupled with thrombopoietin, SCF and Flt-3 ligand
(TSF) for 7 days resulted in a 22.6-fold expansion of total cells, com-
pared with 360.0-fold expansion with TSF alone (p5 0.001). How-
ever, DEAB-culture maintained a significantly higher percentage of
lin- (mean 97.1%) and KSL cells (mean 14.1%) at day 7 as com-
pared to TSF alone (42.6% and 4.7%, respectively; p\ 0.001 and
p5 0.03), indicating that inhibition of ALDH preferentially main-
tained more primitive progenitors in culture than TSF alone.
We then transplanted FACS-sorted donor CD45.11 BM
34-KSL cells or their progeny following culture with TSF alone
or TSF 1 DEAB at limiting doses into lethally irradiated
CD45.21 congenic recipients. At 4 weeks post-transplantat,
DEAB-cultured progeny showed significantly accelerated engraft-
ment in recipient mice, as compared to day 0 34-KSL cells or their
progeny following culture with TSF alone. Using Poisson statistical
analysis, the repopulating cell frequency was found to be 1 in 48.4
for the DEAB-cultured progeny (95% confidence interval: 27.3 –
86.0) as compared to 1 in 99.6; CI: 50.4 – 197.0) within the TSF-
cultured progeny. Unmanipulated BM 34-KSL cells had not yet
shown significant levels of hematopoietic engraftment at week 4
(1 in 1319.4; CI 187.2 – 9298.8). DEAB-cultured progeny also dem-
onstrated significantly higher B2201 and Thy 1.21 lymphoid con-
tribution, as compared to day 0 BM 34-KSL cells (p\ 0.001 and
p\0.001), and significantly higher level ofMac-11/Gr-11myeloid
reconstitution (p \ 0.001), compared with the progeny of TSF
alone. These data demonstrate that pharmacologic inhibition of
ALDH facilitates the differential expansion of hematopoietic pro-
genitors with enhanced early engraftment capacity. This strategy
can be particularly useful to expand human CB grafts to overcome
the delays in engraftment which currently limit this otherwise
attractive source of HSCs for adult transplantation.20
HIGHER CD341 CELL DOSES ARE ASSOCIATED WITH DECREASED RE-
LAPSE RATES FOLLOWING UNRELATED DONOR ALLOGENEIC PERIPH-
ERAL BLOOD STEM CELL TRANSPLANTATION WITH TRENDS TO
IMPROVED DISEASE-FREE SURVIVAL
Nakamura, R.1, Auayporn, N.1, Smith, D.D.2, Palmer, J.2, Sun, J.Y.1,
Schriber, J.3, Pullarkat, V.1, Parker, P.1, Rodriguez, R.1, Stein, A.1,
Rosenthal, J.1, Wang, S.4, Karanas, C.1, Senitzer, D.1, Forman, S.J.1.
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